1. Home
  2. ADAMI vs HTFL Comparison

ADAMI vs HTFL Comparison

Compare ADAMI & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAMI
  • HTFL
  • Stock Information
  • Founded
  • ADAMI N/A
  • HTFL 2007
  • Country
  • ADAMI United States
  • HTFL United States
  • Employees
  • ADAMI N/A
  • HTFL N/A
  • Industry
  • ADAMI Real Estate Investment Trusts
  • HTFL
  • Sector
  • ADAMI Real Estate
  • HTFL
  • Exchange
  • ADAMI Nasdaq
  • HTFL Nasdaq
  • Market Cap
  • ADAMI 2.3B
  • HTFL 2.6B
  • IPO Year
  • ADAMI N/A
  • HTFL 2025
  • Fundamental
  • Price
  • ADAMI $25.22
  • HTFL $33.00
  • Analyst Decision
  • ADAMI
  • HTFL Strong Buy
  • Analyst Count
  • ADAMI 0
  • HTFL 4
  • Target Price
  • ADAMI N/A
  • HTFL $36.00
  • AVG Volume (30 Days)
  • ADAMI N/A
  • HTFL 469.0K
  • Earning Date
  • ADAMI N/A
  • HTFL 01-01-0001
  • Dividend Yield
  • ADAMI N/A
  • HTFL N/A
  • EPS Growth
  • ADAMI N/A
  • HTFL N/A
  • EPS
  • ADAMI N/A
  • HTFL N/A
  • Revenue
  • ADAMI N/A
  • HTFL $136,170,000.00
  • Revenue This Year
  • ADAMI N/A
  • HTFL N/A
  • Revenue Next Year
  • ADAMI N/A
  • HTFL N/A
  • P/E Ratio
  • ADAMI N/A
  • HTFL N/A
  • Revenue Growth
  • ADAMI N/A
  • HTFL 44.32
  • 52 Week Low
  • ADAMI N/A
  • HTFL $26.56
  • 52 Week High
  • ADAMI N/A
  • HTFL $36.68
  • Technical
  • Relative Strength Index (RSI)
  • ADAMI N/A
  • HTFL N/A
  • Support Level
  • ADAMI N/A
  • HTFL N/A
  • Resistance Level
  • ADAMI N/A
  • HTFL N/A
  • Average True Range (ATR)
  • ADAMI 0.00
  • HTFL 0.00
  • MACD
  • ADAMI 0.00
  • HTFL 0.00
  • Stochastic Oscillator
  • ADAMI 0.00
  • HTFL 0.00

About HTFL Heartflow Inc. Common Stock

HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.

Share on Social Networks: